
Patent Claims

1. Compounds of the formula I



I

in which

U denotes CH_2 or CHR^2,

V denotes CH_2, CHR^2 or CO,

W denotes NR^1 or CR^3R^6,

or denotes NH, if U or V denote CHR^2,

R^1 denotes Ar, Het, COA, $COAr^1$, COHet, $CO(CH_2)_nNR^4R^5$, $(CH_2)_nHet$, $(CH_2)_nCONHAr$, $(CH_2)_nCONHHet$, $(CH_2)_nCONR^4R^5$, $(CH_2)_nOH$, $(CH_2)_nOA$ or $(CH_2)_nNR^4R^5$,

R^2 denotes A, Ar^1, Hal, CN, COA, COOH, COOA, $CONR^4R^5$, $SO_2NR^4R^5$, $(CH_2)_nOH$ or $(CH_2)_nNR^4R^5$,

R^3 denotes H, OH or OA,

R^4, R^5 each, independently of one another, denote H or A,

R^6 denotes A or Ar^1,

Ar denotes phenyl, which is mono-, di- or trisubstituted by Hal, A, $O(CH_2)_pCyc$, Alk, $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCOOH$, $(CH_2)_nCOOA$, $S(O)_mA$, phenoxy, benzyloxy, $(CH_2)_nNH_2$, $(CH_2)_nNHA$, $(CH_2)_nNA_2$, $(CH_2)_nCN$, NO_2, $(CH_2)_nCONH_2$, $(CH_2)_nCONHA$, $(CH_2)_nCONA_2$, SO_2NH_2, SO_2NHA, SO_2NA_2, $NHCONH_2$, $(CH_2)_nNHCOA$, $(CH_2)_nNHCOAlk$, $NHCOCH=CH(CH_2)_pNA_2$, CHO, COA, SO_3H, $O(CH_2)_pNH_2$, $O(CH_2)_pNHCOOA$, $O(CH_2)_pNHA$, $O(CH_2)_pNA_2$, $NH(CH_2)_pNH_2$, $NH(CH_2)_pNHCOOA$, $NH(CH_2)_pNHA$, $NH(CH_2)_pNA_2$, $NHCOHet^3$, $COHet^3$, $(CH_2)_nHet^3$, $O(CH_2)_nHet^3$ and/or $O(CH_2)_nCH(OH)(CH_2)$,

Ar^1 denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCOOH$, $(CH_2)_nCOOA$, $S(O)_mA$, phenoxy, benzyloxy, $(CH_2)_nNH_2$, $(CH_2)_nNHA$, $(CH_2)_nNA_2$, $(CH_2)_nCN$, NO_2, $(CH_2)_nCONH_2$, $(CH_2)_nCONHA$, $(CH_2)_nCONA_2$, SO_2NH_2, SO_2NHA, SO_2NA_2, $NHCONH_2$, $(CH_2)_nNHCOA$, CHO, COA and/or SO_3H,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di-, tri- or tetra-substituted by Hal, A, $(CH_2)_nHet^3$, $OHet^3$, $NH(CH_2)_nHet^3$, $(CH_2)_nCOOH$, $(CH_2)_nCOOA$, phenyl, benzyl, CHO, COA, $(CH_2)_nNH_2$, $(CH_2)_nNHA$, $(CH_2)_nNA_2$, CN, $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_pCH(OH)(CH_2)_pOH$, $(CH_2)_pCH(OH)(CH_2)_pOA$, $NH(CH_2)_pNH_2$, $NHSO_2A$, $NASO_2A$, SO_2A, $(CH_2)_nCONR^4R^5$, $(CH_2)_nSO_2NR^4R^5$ and/or =O,

Het^3 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di-, tri- or tetrasubstituted by A, Hal, $(CH_2)_nNH_2$, $(CH_2)_nNHA$, $(CH_2)_nNA_2$, $(CH_2)_nOH$, $(CH_2)_nOA$, COOA, Ar^3 and/or =O,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl and/or in which one or two non-adjacent CH_2 groups may be replaced by O, NH, S, SO, SO_2 and/or by CH=CH groups,

Cyc denotes cyclic alkyl having 3-7 C atoms,

Alk denotes alkenyl or alkinyl having 2, 3, 4, 5 or 6 C-atoms,

Ar^3 denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A,

Hal denotes F, Cl, Br or I,

m denotes 0, 1 or 2,

n denotes 0, 1, 2, 3 or 4,

p denotes 1, 2, 3 or 4,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

Ar denotes phenyl, which is mono-, di- or trisubstituted by Hal, $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCN$, $(CH_2)_nCONH_2$, $(CH_2)_nCONHA$ and/or $(CH_2)_nCONA_2$,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

Ar^1 denotes phenyl

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which

Het denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, dihydro-pyrazolyl, dihydro-pyridyl, dihydropyranyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, 2,3-dihydro-benzo[1,4]dioxinyl, indazolyl or benzothiadiazolyl, each of which is unsubstituted or mono-, di- or trisubstituted by $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCONR^4R^5$, $(CH_2)_nSO_2NR^4R^5$ and/or =O,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to one or more of Claims 1-4 in which

Het^3 denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, 2,3-dihydro-pyrazolyl, 1,2-dihydro-pyridyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, 4,5-dihydro-1H-[1,2,4]triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, tetrahydro-benzothiophenyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by A, $(CH_2)_nOH$, $(CH_2)_nOA$ and/or =O,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to one or more of Claims 1-5 in which

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Compounds according to one or more of Claims 1-6 in which in which

U denotes CH_2,

V denotes CH_2, CHR^2 or CO,

W denotes NR^1 or CR^3R^6,

or denotes NH, if U or V denote CHR^2,

R^1 denotes Ar, Het, COA, $COAr^1$, COHet, $CO(CH_2)_nNR^4R^5$, $(CH_2)_nHet$, $(CH_2)_nCONHAr$, $(CH_2)_nCONHHet$, $(CH_2)_nCONR^4R^5$, $(CH_2)_nOH$, $(CH_2)_nOA$ or $(CH_2)_nNR^4R^5$,

R^2 denotes A, Ar^1, $CONR^4R^5$ or $(CH_2)_nOH$,

R^3 denotes H, OH or OA,

R^4, R^5 each, independently of one another, denote H or A,

R^6 denotes A or Ar^1,

Ar denotes phenyl, which is mono-, di- or trisubstituted by Hal, $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCN$, $(CH_2)_nCONH_2$, $(CH_2)_nCONHA$ and/or $(CH_2)_nCONA_2$,

Ar^1 denotes phenyl,

Het denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, dihydro-pyrazolyl, dihydro-pyridyl, dihydropyranyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, 2,3-dihydro-benzo[1,4]dioxinyl, indazolyl or benzothiadiazolyl, each of which is unsubstituted or mono-, di- or trisubstituted by $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCONR^4R^5$, $(CH_2)_nSO_2NR^4R^5$ and/or =O,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl,

n denotes 0, 1, 2, 3 or 4,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

8. Compounds according to one or more of Claims 1-7 in which in which

U denotes CH_2,

V denotes CH_2,

W denotes NR^1,

R^1 denotes Ar, Het, COA, $COAr^1$, COHet, $CO(CH_2)_nNR^4R^5$, $(CH_2)_nHet$, $(CH_2)_nCONHAr$, $(CH_2)_nCONHHet$, $(CH_2)_nCONR^4R^5$, $(CH_2)_nOH$, $(CH_2)_nOA$ or $(CH_2)_nNR^4R^5$,

R^4, R^5 each, independently of one another, denote H or A,

Ar denotes phenyl, which is mono-, di- or trisubstituted by Hal, $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCN$, $(CH_2)_nCONH_2$, $(CH_2)_nCONHA$ and/or $(CH_2)_nCONA_2$,

Ar^1 denotes phenyl,

Het denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, dihydro-pyrazolyl, dihydro-pyridyl, dihydropyranyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, 2,3-dihydro-benzo[1,4]dioxinyl, indazolyl or benzothiadiazolyl, each of which is unsubstituted or mono-, di- or trisubstituted by $(CH_2)_nOH$, $(CH_2)_nOA$, $(CH_2)_nCONR^4R^5$, $(CH_2)_nSO_2NR^4R^5$ and/or =O,

A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl,

n denotes 0, 1, 2, 3 or 4,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

9. Compounds according to Claim 1, selected from the group

No.	Name and/or structure
"A3"	2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A5"	2-[4-(3-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A6"	2-[4-(4-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A7"	2-[4-(3-methoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A8"	2-[4-(4-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

"A9"	2-[4-(2-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A10"	2-(4-trifluoromethylpiperidin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A11"	2-[4-(3-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A12"	2-[4-(2-methoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A13"	2-(4-tert-butylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A14"	2-[4-(4-methoxyphenyl)-3-oxopiperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A15"	2-[4-(piperidine-1-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A16"	2-[4-(6-hydroxypyridin-2-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A17"	2-(4-benzoylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A18"	N-pyridin-2-yl-2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]acetamide
"A19"	2-(4-acetylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A20"	2-[4-(morpholine-4-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A21"	2-[4-(3-aminopropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A22"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]pyridine-3-carboxamide
"A23"	2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]-N-pyridin-3-ylacetamide


"A24"	2-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A25"	2-[4-(2-hydroxyethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A26"	2-[4-[2-(2-pyridyl)ethyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A27"	2-[4-(piperidine-2-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A28"	4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide
"A29"	2-[3-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A30"	(2R)-1-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide
"A31"	2-[(2R)-2-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A32"	2-[4-(3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A33"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile
"A34"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzamide
"A35"	2-(4-hydroxy-4-phenyl-1-piperidyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A36"	2-[4-(4-fluoro-2-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A37"	2-[4-(2,4-dimethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A38"	2-[4-(2-chloro-4-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

"A39"	2-[4-(2-chloro-4-fluoro-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A40"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]acetamide
"A41"	2-(3-phenylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A42"	2-[4-(2-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A43"	2-[4-[2-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A44"	2-[4-(6-methoxypyridazin-3-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A45"	4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile
"A46"	2-[4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]phenyl]acetonitrile
"A47"	2-[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A48"	2-[4-(4-ethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A49"	2-[4-(4-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A50"	2-[4-(4-trifluoromethylphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A51"	2-[4-(6-methoxy-3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A52"	2-[4-(5-methoxy-2-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A53"	2-[4-hydroxy-4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

"A54"	2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A55"	2-[4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A56"	2-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A57"	2-[4-[2-(1-hydroxy-1-methyl-ethyl)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one


and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

10. Process for the preparation of compounds of the formula I according to Claims 1-9 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that
a compound of the formula II



II

is reacted with a compound of the formula III



III

in which U, V and W have the meanings indicated in Claim 1,

and/or
a base or acid of the formula I is converted into one of its salts.

11. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates, tautomers and

stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

12. Compounds of the formula I and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

13. Compounds according to claim 12 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.

14. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

15. Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

16. The compound
2-(4-tert-butyl-piperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one ("B1"),
and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

Patent Claims

1. Compounds selected from the group

No.	Name and/or structure
"A3"	2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A5"	2-[4-(3-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A6"	2-[4-(4-fluorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A7"	2-[4-(3-methoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A8"	2-[4-(4-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A9"	2-[4-(2-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A10"	2-(4-trifluoromethylpiperidin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A11"	2-[4-(3-chlorophenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A12"	2-[4-(2-methoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A13"	2-(4-tert-butylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A14"	2-[4-(4-methoxyphenyl)-3-oxopiperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A15"	2-[4-(piperidine-1-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

"A16"	2-[4-(6-hydroxypyridin-2-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A17"	2-(4-benzoylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A18"	N-pyridin-2-yl-2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]acetamide
"A19"	2-(4-acetylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A20"	2-[4-(morpholine-4-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A21"	2-[4-(3-aminopropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A22"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]pyridine-3-carboxamide
"A23"	2-[4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)piperazin-1-yl]-N-pyridin-3-ylacetamide
"A24"	2-[4-(2,2-dimethylpropanoyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A25"	2-[4-(2-hydroxyethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A26"	2-[4-[2-(2-pyridyl)ethyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A27"	2-[4-(piperidine-2-carbonyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A28"	4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide
"A29"	2-[3-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A30"	(2R)-1-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazine-2-carboxamide

"A31"	2-[(2R)-2-(hydroxymethyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A32"	2-[4-(3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A33"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile
"A34"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzamide
"A35"	2-(4-hydroxy-4-phenyl-1-piperidyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A36"	2-[4-(4-fluoro-2-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A37"	2-[4-(2,4-dimethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A38"	2-[4-(2-chloro-4-methoxy-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A39"	2-[4-(2-chloro-4-fluoro-phenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A40"	2-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]acetamide
"A41"	2-(3-phenylpiperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A42"	2-[4-(2-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A43"	2-[4-[2-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A44"	2-[4-(6-methoxypyridazin-3-yl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A45"	4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]benzonitrile

"A46"	2-[4-[4-(4-oxo-5,6,7,8-tetrahydro-3H-quinazolin-2-yl)piperazin-1-yl]phenyl]acetonitrile
"A47"	2-[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A48"	2-[4-(4-ethoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A49"	2-[4-(4-isopropoxyphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A50"	2-[4-(4-trifluoromethylphenyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A51"	2-[4-(6-methoxy-3-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A52"	2-[4-(5-methoxy-2-pyridyl)piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A53"	2-[4-hydroxy-4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A54"	2-[4-(2-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A55"	2-[4-(4-methoxy-phenyl)-piperidin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A56"	2-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one
"A57"	2-[4-[2-(1-hydroxy-1-methyl-ethyl)phenyl]piperazin-1-yl]-5,6,7,8-tetrahydro-3H-quinazolin-4-one

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and

optionally an pharmaceutically acceptable carrier, excipient or vehicle.

3. Compounds according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

4. Compounds according to claim 3 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.

5. Medicaments comprising at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

6. Set (kit) consisting of separate packs of

(a) an effective amount of a compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and

(b) an effective amount of a further medicament active ingredient.

7. The compound

2-(4-tert-butyl-piperazin-1-yl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one ("B1"),
and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.